We’ve been quietly working on something huge.
Today we’re proud to announce we’ve raised our Series A from an excellent group of investors. The round was led by health tech specialists Catalyst Health Ventures and Genoa Ventures with participation from Dexcom Ventures, OSF Ventures, MedMountain Ventures, Wavemaker 360, Physician Angels Fund, and Salt Lake City Angels.
We received FDA clearance for our first product last year, and we’re excited to continue developing toward our vision of a world where EEG is readily accessible, available, and actionable. Two-thirds of the U.S. population lack ready access to EEGs and most emergency departments lack the capability to adequately screen for seizures monitor EEG (Ward et al., 2012. Neurocrit Care. 16(2):232-40.). We’re excited to solve this problem. Our platform is intended to give more control to patients, clinicians, and caregivers. In the not too distant future, we plan to use our deep EEG dataset to create novel biomarkers for neurological disorders.
What does this mean for clinicians? Our Series A enables us to begin initial commercialization for our FDA-cleared product as we begin our roll out to select hospitals. We’re here to help you provide the care you want to your patients and make data-based decisions. Don’t hesitate to reach out!
What does this mean for patients? We want to unlock the power of EEG to help neurology reach previously inaccessible places. This financing will allow us to continue developing toward our products outside of the hospital.
Do you want to be a part of the next neurology pioneer? We’re hiring across the board! We have open roles for both technical and non-technical positions all over the country, with more to come. Take a look at our website to apply!
Read more from our press release.